Moderna Agrees to Pay Roivant Up to $2.25 Billion to Resolve mRNA Vaccine Patent Dispute

Moderna is set to pay Roivant up to $2.25 billion as part of a settlement that resolves a major patent lawsuit related to mRNA vaccine technology. This agreement brings significant financial benefits to Arbutus and Roivant, while enabling Moderna to avoid a potentially severe legal setback.